The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Synthetic Mammalian Prions
Abstract
Recombinant mouse prion protein (recMoPrP) produced in Escherichia coli was polymerized into amyloid fibrils that represent a subset of β sheet–rich structures. Fibrils consisting of recMoPrP(89–230) were inoculated intracerebrally into transgenic (Tg) mice expressing MoPrP(89–231). The mice developed neurologic dysfunction between 380 and 660 days after inoculation. Brain extracts showed protease-resistant PrP by Western blotting; these extracts transmitted disease to wild-type FVB mice and Tg mice overexpressing PrP, with incubation times of 150 and 90 days, respectively. Neuropathological findings suggest that a novel prion strain was created. Our results provide compelling evidence that prions are infectious proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Novel Proteinaceous Infectious Particles Cause Scrapie
Prusiner, S. B. (1982) · Science · doi:10.1126/science.6801762 · Cited by 5,118
Self-citationLevine, H. (1993) · Protein Science · doi:10.1002/pro.5560020312 · Cited by 2,264
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Mice devoid of PrP are resistant to scrapie
Büeler, H., Aguzzi, A., Sailer, A., Greiner, R.-A., Autenried, P., Aguet, M., & Weissmann, C. (1993) · Cell · doi:10.1016/0092-8674(93)90360-3 · Cited by 2,100
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735
Prion Diseases of Humans and Animals: Their Causes and Molecular Basis
Collinge, J. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.519 · Cited by 1,344
Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding
Saborio, G. P., Permanne, B., & Soto, C. (2001) · Nature · doi:10.1038/35081095 · Cited by 1,310
Identification of a Protein That Purifies with the Scrapie Prion
Bolton, D. C., McKinley, M. P., & Prusiner, S. B. (1982) · Science · doi:10.1126/science.6815801 · Cited by 1,280
Self-citation[URE3] as an Altered URE2 Protein: Evidence for a Prion Analog in Saccharomyces cerevisiae
Wickner, R. B. (1994) · Science · doi:10.1126/science.7909170 · Cited by 1,209
Nature of the Scrapie Agent: Self-replication and Scrapie
GRIFFITH, J. S. (1967) · Nature · doi:10.1038/2151043a0 · Cited by 1,161
Cited by
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
A General Model of Prion Strains and Their Pathogenicity
Collinge, J., & Clarke, A. R. (2007) · Science · doi:10.1126/science.1138718 · Cited by 1,057
Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971
Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies
Ciechanover, A., & Kwon, Y. T. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.117 · Cited by 898
In Vitro Generation of Infectious Scrapie Prions
Castilla, J., Saá, P., Hetz, C., & Soto, C. (2005) · Cell · doi:10.1016/j.cell.2005.02.011 · Cited by 790
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
“Recently, in vitro production of recombinant mouse PrP SC capable of disease transmission provided compelling evidence that prions are the infectious protei”
BackgroundGenerating a Prion with Bacterially Expressed Recombinant Prion Protein
Wang, F., Wang, X., Yuan, C.-G., & Ma, J. (2010) · Science · doi:10.1126/science.1183748 · Cited by 661
The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease
King, O. D., Gitler, A. D., & Shorter, J. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.016 · Cited by 644
Formation of native prions from minimal components in vitro
Deleault, N. R., Harris, B. T., Rees, J. R., & Supattapone, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702662104 · Cited by 631
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622
“The failure of seeding by synthetic Ab was not unanticipated, in that the induction of prion disease also has been difficult to achieve with PrP generated in vitro.(57) It is possible that the aggregation of synthetic Ab under suitable (but as yet undefined) conditions will yield a more effective in vivo seed, as was…”
ResultThe physical basis of how prion conformations determine strain phenotypes
Tanaka, M., Collins, S. R., Toyama, B. H., & Weissman, J. S. (2006) · Nature · doi:10.1038/nature04922 · Cited by 593
Biology of Amyloid: Structure, Function, and Regulation
Greenwald, J., & Riek, R. (2010) · Structure · doi:10.1016/j.str.2010.08.009 · Cited by 575
Prions as adaptive conduits of memory and inheritance
Shorter, J., & Lindquist, S. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1616 · Cited by 555
“Furthermore, prions assemble into an ensemble of related, but structurally distinct, transmissible state”
BackgroundMolecular structure of amyloid fibrils: insights from solid-state NMR
Tycko, R. (2006) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004173 · Cited by 527
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
A Unifying Role for Prions in Neurodegenerative Diseases
Prusiner, S. B. (2012) · Science · doi:10.1126/science.1222951 · Cited by 491
Self-citationPeptide‐Based Nanotubes and Their Applications in Bionanotechnology
Gao, X., & Matsui, H. (2005) · Advanced Materials · doi:10.1002/adma.200401849 · Cited by 478
Biology and Genetics of Prions Causing Neurodegeneration
Prusiner, S. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155524 · Cited by 455
Self-citationCorrelation of structural elements and infectivity of the HET-s prion
Ritter, C., Maddelein, M.-L., Siemer, A. B., Lührs, T., Ernst, M., Meier, B. H., Saupe, S. J., & Riek, R. (2005) · Nature · doi:10.1038/nature03793 · Cited by 437
The Prion's Elusive Reason for Being
Aguzzi, A., Baumann, F., & Bremer, J. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125620 · Cited by 418
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions
Stöhr, J., Watts, J. C., Mensinger, Z. L., Oehler, A., Grillo, S. K., DeArmond, S. J., Prusiner, S. B., & Giles, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206555109 · Cited by 361
Self-citationA Test for Creutzfeldt–Jakob Disease Using Nasal Brushings
Orrú, C. D., Bongianni, M., Tonoli, G., Ferrari, S., Hughson, A. G., Groveman, B. R., Fiorini, M., Pocchiari, M., Monaco, S., Caughey, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315200 · Cited by 355
Protein Misfolding and Neurodegeneration
Soto, C., & Estrada, L. D. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.56 · Cited by 352
Molecular Mechanisms of Prion Pathogenesis
Aguzzi, A., Sigurdson, C., & Heikenwaelder, M. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154326 · Cited by 351
Atarashi, R., Moore, R. A., Sim, V. L., Hughson, A. G., Dorward, D. W., Onwubiko, H. A., Priola, S. A., & Caughey, B. (2007) · Nature Methods · doi:10.1038/nmeth1066 · Cited by 350
Weissmann, C. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1025 · Cited by 346
Molecular architecture of human prion protein amyloid: A parallel, in-register β-structure
Cobb, N. J., Sönnichsen, F. D., Mchaourab, H., & Surewicz, W. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706522104 · Cited by 326
Getting a Grip on Prions: Oligomers, Amyloids, and Pathological Membrane Interactions
Caughey, B., Baron, G. S., Chesebro, B., & Jeffrey, M. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082907.145410 · Cited by 323
Cell-to-cell transmission of non-prion protein aggregates
Lee, S.-J., Desplats, P., Sigurdson, C., Tsigelny, I., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.145 · Cited by 309
Amyloid Structure: Conformational Diversity and Consequences
Toyama, B. H., & Weissman, J. S. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090908-120656 · Cited by 304
Prions and their partners in crime
Caughey, B., & Baron, G. S. (2006) · Nature · doi:10.1038/nature05294 · Cited by 295
Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins
Munishkina, L. A., & Fink, A. L. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.03.015 · Cited by 294
Prion-like disorders: blurring the divide between transmissibility and infectivity
Cushman, M., Johnson, B. S., King, O. D., Gitler, A. D., & Shorter, J. (2010) · Journal of Cell Science · doi:10.1242/jcs.051672 · Cited by 289
Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z.-X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903200106 · Cited by 279
Recombinant prion protein induces a new transmissible prion disease in wild-type animals
Makarava, N., Kovacs, G. G., Bocharova, O., Savtchenko, R., Alexeeva, I., Budka, H., Rohwer, R. G., & Baskakov, I. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0633-x · Cited by 275
Self-citationAmyloids, prions and the inherent infectious nature of misfolded protein aggregates
Soto, C., Estrada, L., & Castilla, J. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.01.002 · Cited by 266
Copper and the Prion Protein: Methods, Structures, Function, and Disease
Millhauser, G. L. (2007) · Annual Review of Physical Chemistry · doi:10.1146/annurev.physchem.58.032806.104657 · Cited by 263
Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates
Falcon, B., Cavallini, A., Angers, R., Glover, S., Murray, T. K., Barnham, L., Jackson, S., O'Neill, M. J., Isaacs, A. M., Hutton, M. L., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589309 · Cited by 254
Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target
Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202
“Unique properties of PrP structure are associated with different incubation times and pathologies in animal models (20, 21).”
BackgroundUgalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
Prions and protein-folding diseases: Review: Prions and protein-folding diseases
Norrby, E. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02387.x · Cited by 75
Makarava, N., Chang, J. C.-Y., Molesworth, K., & Baskakov, I. V. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104783 · Cited by 64
Self-citationDistinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease
Kim, C., Haldiman, T., Kang, S.-G., Hromadkova, L., Han, Z. Z., Chen, W., Lissemore, F., Lerner, A., de Silva, R., Cohen, M. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg0253 · Cited by 55
Prion-Like Behavior of Amyloid-β
Kim, J., & Holtzman, D. M. (2010) · Science · doi:10.1126/science.1198314 · Cited by 30
Understanding the natural variability of prion diseases
Geissen, M., Krasemann, S., Matschke, J., & Glatzel, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.041 · Cited by 24
Innate Immune Tolerance in Microglia Does Not Impact on Central Nervous System Prion Disease
Pal, R., Bradford, B. M., & Mabbott, N. A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.918883 · Cited by 7
Metadata
- Authors
- Legname, G., Baskakov, I. V., Nguyen, H.-O. B., Riesner, D., Cohen, F. E., DeArmond, S. J., & Prusiner, S. B.
- Venue
- Science
- Published
- 2004-07-30
- Volume
- 305
- Issue
- 5684
- Pages
- 673-676
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2057293794
- Cited by
- 1,021
- References
- 65
- FWCI
- 35.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.